Skip to main content
  • Book
  • © 1989

New Developments in Antirheumatic Therapy

Part of the book series: Inflammation and Drug Therapy Series (IDTH, volume 3)

Buying options

eBook USD 59.99
Price excludes VAT (USA)
  • ISBN: 978-94-009-1253-3
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book USD 79.99
Price excludes VAT (USA)

This is a preview of subscription content, access via your institution.

Table of contents (12 chapters)

  1. Front Matter

    Pages i-viii
  2. Recent developments in antirheumatic therapy

    • P. Nash, B. L. Hazleman
    Pages 1-28
  3. Osteoarthritis: a metabolic disorder

    • C. W. Denko
    Pages 29-35
  4. Animal models of arthritic disease: influence of novel compared with classical antirheumatic agents

    • I. M. Hunneyball, M. E. J. Billingham, K. D. Rainsford
    Pages 93-131
  5. Novel eicosanoid inhibitors

    • Lisa A. Marshall, Joseph Chang
    Pages 133-151
  6. New steroidal anti-inflammatory drugs

    • Henry J. Lee, Ann S. Heiman, Irach B. Taraporewala
    Pages 153-186
  7. Oxyradicals, inflammation and drugs acting on oxyradical production

    • Dennis V. Parke, Andrew M. Symons, Ann L. Parke
    Pages 187-206
  8. Gold(I)-thiolates: slow-acting anti-arthritic drugs

    • Davin R. Haynes, Michael W. Whitehouse
    Pages 207-233
  9. Interleukin 1: past, present, future

    • Michael C. Powanda, Elizabeth D. Moyer
    Pages 255-276
  10. The T cell as a therapeutic target

    • Ivan G. Otterness, Marcia L. Bliven
    Pages 277-304
  11. Superoxide dismutase modifications for anti-inflammatory therapy

    • F. M. Veronese, A. Conforti, G. P. Velo
    Pages 305-314
  12. Back Matter

    Pages 315-328

About this book

At present we may be at the cross-roads in the therapeutic approaches we have for the treatment of the 100 or more rheumatic conditions. This is be­ cause we now recognise that although some advances have been made with the development of a large range of non-steroidal and steroidal drugs during the past two decades or so, we now recognise that many, if not all, of these have rather limited effects on many of the disease processes which underlie the manifestations of the various rheumatic states. Advances in molecular bi- 010gy in the past 5-10 years have enabled these tools to be applied extensive­ ly for developing further our understanding of the rheumatic disease processes. In some cases these molecular tools (e. g. ,),-interferon, interleukin- 2, T-cell antibodies) have been directly employed as therapies themselves. While the outcome from trials with such agents in rheumatoid arthritis in particular has not been as would have been hoped, these results as with cy­ closporin A and low-dose methotrexate in the therapy of rheumatoid arth­ ritis have given us important indications for the approach employing what are generally described as "immunomodulators" to control this disease. But this may not be the same type of approach which is desirable for all types of rheumatic conditions. Indeed, even the way which the present range of drugs and other therapies are applied may not be the most effective and safe means of treating different types of arthritic conditions.

Keywords

  • Arthritis
  • drug
  • drug development
  • inflammation
  • osteoarthritis
  • research
  • rheumatoid arthritis
  • toxicity

Editors and Affiliations

  • Department of Biomedical Sciences, McMaster University Faculty of Health Sciences, Hamilton, Canada

    K. D. Rainsford

  • Institute of Pharmacology, University of Verona, Italy

    G. P. Velo

Bibliographic Information

Buying options

eBook USD 59.99
Price excludes VAT (USA)
  • ISBN: 978-94-009-1253-3
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book USD 79.99
Price excludes VAT (USA)